Abstract 15922: Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Statin-treated Women With Persistent High Triglycerides: Results From the ANCHOR Study

Introduction: Few studies examined novel triglyceride (TG)-lowering therapies in women, despite elevated TGs being a stronger predictor of cardiovascular disease (CVD) in women than men. Hypothesis: To conduct a subgroup analysis of the effect of icosapent ethyl (IPE), a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester 4 g/day vs placebo on TGs (primary efficacy variable), and other atherogenic and inflammatory parameters among women in the 12-week placebo-controlled ANCHOR study. Methods: ANCHOR randomized 702 statin-treated patients (39% women) at increased CVD risk with TGs 200-499 mg/dL despite low-density lipoprotein cholesterol (LDL-C) control (40- Results: IPE 4 g/day (n=87) significantly reduced TGs (–22%; P P >0.05) vs placebo (n=86) in women from the ANCHOR study. Significant improvements in other atherogenic and inflammatory parameters were also observed vs placebo (Figure). IPE 4 g/day significantly increased plasma (+667%; P P Conclusions: Among statin-treated women with baseline TGs 200-499 mg/dL, IPE 4 g/day significantly reduced TGs and several other atherogenic and inflammatory parameters without increasing LDL-C compared with placebo. The clinical implications of these findings are being evaluated in the REDUCE-IT cardiovascular outcomes study.